SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Cervical Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Cervical Cancer.

Related Posts

STAT+: Here are the cancer drugs Pfizer thinks could re...

Feb 29, 2024

NorthStar and Convergent expand deal for prostate cance...

Aug 15, 2024

Immune Thrombocytopenia by NovelMed Therapeutics for Id...

Jul 1, 2023